Addiction and the Criminal Legal System: What Each Position Is Protecting

She completed the eighteen-month drug court program in Albuquerque and stood in a courtroom as the judge shook her hand and told her she was a different person than the one who had walked in. She had been tested twice a week, attended counseling three times a week, checked in with a case manager, maintained housing, and stayed employed. The charge on her record was dismissed. She credits the program with her life. She does not think she would have entered treatment voluntarily — the structure, even the supervision, was what made it possible.

He enrolled in a different drug court the same year and was terminated from the program after a positive test in month eleven. Under the terms he had agreed to, termination meant he faced the original charge without the benefit of the plea agreement the drug court had structured. He received a sentence longer than he would have gotten if he had simply pled guilty at the outset. His lawyer later told him that the positive test was consistent with what treatment providers call a relapse — a well-documented part of the disorder — and that the drug court's response to it had treated a medical event as a disciplinary failure. He is not sure what he would tell someone in the same position now.

Both of them encountered the same institutional design: a program that threads treatment through the architecture of the criminal legal system. That design has four genuinely different assessments, and each of them is protecting something real.

What drug court and therapeutic jurisprudence advocates are protecting

People who support drug courts and the broader project of problem-solving courts are protecting something that conventional criminal justice misses.

They are protecting access to treatment for people the public health system does not reach. The American substance use disorder treatment infrastructure is substantially underfunded and is not accessible to many people who need it — particularly those without insurance, stable housing, or knowledge of how to navigate a fragmented system. The criminal legal system reaches people at a moment of crisis that may be their only point of institutional contact. A drug court that diverts someone into treatment catches a person the health system missed. Michael Rempel's evaluation of the New York State drug court system found significant reductions in re-arrest and incarceration rates compared to similar defendants processed conventionally. The argument is not that criminal legal involvement is ideal — it is that it is often the only lever available.

They are protecting structured accountability that enables recovery. The therapeutic jurisprudence framework holds that the courtroom relationship itself — the judge, the case manager, the regular check-ins, the graduated sanctions and incentives — can be a therapeutic mechanism. Research on motivational dynamics suggests that external structure, consistently applied, can support the development of internal motivation over time. Participants who complete drug courts consistently report that the structured expectations were part of what worked, not merely an obstacle to treatment. This is the strongest version of the drug court argument: not coercion as a substitute for treatment, but structure as an enabling condition for it.

They are protecting communities from the consequences of untreated addiction. Property crime, domestic violence, overdose calls, and neighborhood disorder are not abstractions in the communities most affected. The therapeutic jurisprudence position holds that effective intervention in addiction produces community safety outcomes, and that a system which processes and incapacitates without treating produces neither recovery nor safety — only a revolving door. Drug courts, on this view, are protecting both the individual who needs treatment and the community that bears the costs of untreated substance use disorders.

What voluntary care advocates and coercion critics are protecting

A distinct position — held by many addiction medicine researchers, civil liberties advocates, and harm reduction practitioners — supports treatment and opposes coercion to obtain it. These advocates are protecting something the drug court model can undermine.

They are protecting the therapeutic alliance that makes treatment work. The evidence base for effective addiction treatment consistently identifies the quality of the relationship between a person and their treatment provider as among the most powerful predictors of outcome. Maia Szalavitz, drawing on the neuroscience and psychology of addiction, argues in Unbroken Brain that addiction is better understood as a developmental learning disorder than as either a moral failure or a purely neurological disease — and that coercive treatment is antithetical to the kind of learning that recovery requires. Motivational interviewing, the evidence-based counseling technique developed by William Miller and Stephen Rollnick, is specifically designed to work with ambivalence rather than override it; its effectiveness depends on conditions of safety, not surveillance.

They are protecting people from being swept into a wider net. The net-widening critique of drug courts, developed by researchers and documented by Alexandra Natapoff in her analysis of the misdemeanor system, holds that diversion programs often divert people not from prison but from dismissal or minor sanctions. Drug courts can create a new population of supervised probationers — people whose original offense would not have resulted in incarceration, and who are now subject to years of testing, check-ins, and the constant threat that a relapse will convert a minor charge into a felony. For this population, the drug court has not been an alternative to punishment; it has been a punishment disguised as treatment.

They are protecting medication-assisted treatment from ideological exclusion. Methadone maintenance and buprenorphine (Suboxone) are among the most evidence-supported interventions for opioid use disorder — they reduce overdose mortality, HIV transmission, and criminal legal involvement. Many drug courts have historically prohibited or discouraged MAT, treating it as substituting one drug for another rather than as medical treatment. The NADCP has updated its standards to encourage MAT, but implementation is uneven, and participants in drug courts that ban or discourage MAT are required to maintain sobriety without the tools with the strongest evidence base. The coercion critique includes this specific claim: the drug court model, by requiring abstinence as a condition of program completion, sometimes demands a standard of recovery that the evidence does not support.

What harm reduction advocates inside carceral settings are protecting

There is a third position that operates at the intersection of harm reduction and incarceration policy. These advocates are not primarily arguing about whether people should enter the criminal legal system — they are addressing what happens to people who are already in it.

They are protecting lives in the period of highest overdose risk. The most important single data point in the research on incarceration and addiction is Ingrid Binswanger and colleagues' 2007 study in the New England Journal of Medicine: the overdose mortality rate among people released from prison is approximately twelve times higher in the first two weeks post-release than in the general population. Incarceration forces involuntary abstinence, which lowers tolerance; release returns people to the same social and environmental conditions in which their drug use occurred, but with a body that can no longer process the doses they previously used. The result is a systematic death spike that is entirely predictable and largely preventable. Naloxone distribution at release, MAT initiation in the final weeks before release, and community linkages established before release — rather than after — would substantially reduce these deaths.

They are protecting people from acquiring and transmitting HIV and hepatitis C while incarcerated. Drug use, including injection drug use, continues inside prisons and jails. In the absence of harm reduction infrastructure — clean needles, naloxone, drug checking — people use shared equipment in conditions of extreme secrecy that make it more dangerous than use outside. HIV and hepatitis C rates in carceral settings are dramatically higher than in the general population, and incarceration has been a documented driver of both epidemics. Needle exchange programs in prisons operate in Canada, Spain, Switzerland, and several other countries with documented reductions in blood-borne infection rates; they are rare in the United States. The harm reduction position is that denying these services does not prevent drug use — it just makes it more deadly.

They are protecting medication continuity as a civil rights claim. People who are on buprenorphine or methadone for opioid use disorder — prescribed by a physician, maintained as a medical treatment — routinely have that treatment discontinued upon incarceration. Josiah Rich and colleagues at Brown University have documented the consequences: withdrawal, relapse, overdose on release. The harm reduction position holds that discontinuing prescribed medical treatment upon incarceration is not a policy choice but a civil rights violation, and that the correct frame is continuity of care, not accommodation of a vice. Several successful lawsuits have established this claim in particular jails and prisons, but it is not yet a universal standard.

What structural critics and transformative justice advocates are protecting

The fourth position holds that the previous three are, in different ways, working within a frame that needs to be questioned.

They are protecting the recognition that the criminal legal system is not a health care system. Drug courts may be preferable to incarceration as a response to addiction — but the comparison is between two responses neither of which is adequate to a health and social problem. The resources invested in drug courts, supervision, testing, and case management within a criminal legal framework could, in principle, support community-based treatment infrastructure that does not require criminal legal contact as a condition of access. The structural critique holds that directing health resources through criminal legal channels is not a solution to inadequate health infrastructure — it is an adaptation to it that makes that inadequacy sustainable without addressing it.

They are protecting the recognition that addiction's root conditions are poverty, trauma, and social disconnection. Johann Hari's investigation of addiction policy across three continents found that the most durable recoveries were built not through treatment programs or criminal legal supervision but through the restoration of meaningful social connection — work, relationships, housing, purpose. The rat park studies by Bruce Alexander, which found that rats with enriched social environments refused the drug-laced water that isolated rats consumed compulsively, offer an animal model for this finding. The structural position holds that a criminal legal system response to addiction addresses the behavioral surface of a condition whose roots are in economic and social deprivation — and that even a well-designed drug court cannot fix what the drug court is not designed to address.

They are protecting people from therapeutic net-widening. This is the concept that most sharply distinguishes the structural critique from the coercion critique: a program can be genuinely therapeutic and still extend the reach of the carceral state in ways that cause net harm. A drug court that diverts someone who would have been incarcerated is preferable to incarceration. A drug court that supervises someone who would have been fined or dismissed — and subjects them to years of testing, reporting, and the risk that a relapse will convert a minor charge into a serious one — is not therapeutic diversion but therapeutic expansion of carceral control. The problem is structural: the drug court exists within a system whose default resource is surveillance, and surveillance is what it supplies even when its intentions are otherwise.

Where the real disagreement lives

The debate about addiction and the criminal legal system contains, in compressed form, several disagreements that surface elsewhere but are unusually visible here.

Which comparison to make. Drug courts look effective when compared to conventional incarceration — and that comparison is real, because people who would otherwise be incarcerated are genuinely better off in drug court. Drug courts look less effective when compared to voluntary community-based treatment, which consistently produces better outcomes without the risks of net-widening and the costs of coercion. Which comparison you make shapes whether drug courts look like a success. Both comparisons are valid. The question is which alternative is actually available — and what it would take to make the better alternative more available.

The governance gap. Drug court judges operate with substantial discretion and limited accountability. The decision to terminate a participant, and what sentence follows termination, is largely within the judge's control, typically not subject to normal appellate review, and varies substantially across judges and jurisdictions. The therapeutic apparatus creates a relationship of dependency — participants have often waived their trial rights to enter the program — and the judge who manages that relationship has powers that a conventional sentencing judge would not have. The drug court system has not developed accountability mechanisms commensurate with those powers.

Treatment as a gateway or treatment as a destination. The harm reduction position and the drug court position agree that people with substance use disorders should have access to treatment. They disagree about what treatment means. For harm reduction advocates, MAT continuity, naloxone, and supervised consumption are treatment — they reduce death, disease, and suffering regardless of whether they produce abstinence. For therapeutic jurisprudence advocates, drug courts are the gateway to a recovery-oriented system — the structure that enables someone to engage with treatment who would not engage without it. The word "treatment" carries different meanings in these frameworks, and arguing past each other is common.

Whether the carceral setting can be made therapeutic. The harm reduction camp says yes — MAT, naloxone, needle exchanges, and overdose prevention can be implemented within carceral settings and should be, now. The structural camp says the question is wrongly framed — the goal should be reducing carceral contact, not making carceral settings more comfortable. This is not a disagreement about harm reduction as a concept; it is a disagreement about which interventions deserve priority. Both camps want people with substance use disorders to have access to health care. They disagree about whether the energy spent improving conditions inside prisons would be better spent reducing the prison population.

What sensemaking surfaces

The addiction and criminal legal system debate is downstream of three prior debates that it usually inherits without examination. The first is the debate about what addiction is — a moral failure, a brain disease, a learning disorder, or a social and economic condition. The second is the debate about what the criminal legal system is for — retribution, deterrence, incapacitation, or rehabilitation. The third is the debate about whether the health care system should be the primary institution responsible for substance use disorders, and if so, how to fund and structure it. Each of these prior debates has multiple positions. The addiction and criminal legal system debate inherits all of them, which is part of why it generates so much heat with so little resolution.

The post-release overdose mortality data is not widely known outside addiction medicine, and it should be. The systematic death spike in the two weeks after release from prison is not a secondary finding or a contested claim — it is one of the most consistent and replicated findings in the epidemiology of addiction. A system that incarcerates people, forces involuntary abstinence, and releases them without MAT, naloxone, or community connection is not a treatment system and is not a safety system; it is producing predictable deaths and calling them individual failures. The harm reduction position inside prisons is correct on the specific and immediate claim: these people can be kept alive with interventions that exist now.

The net-widening critique is the hardest to evaluate and the most important to take seriously. Drug courts that genuinely divert people from incarceration are a meaningful improvement. Drug courts that expand surveillance over people who would otherwise have exited the system are not. The problem is that these two populations are hard to distinguish in advance, the incentives for drug court administrators run toward expansion, and the design features that produce net-widening — low-level charge eligibility, wide judicial discretion, long supervision periods — are the same features that make drug courts attractive as a policy tool. Taking the structural critique seriously does not require opposing drug courts; it requires designing them with enough specificity to avoid becoming what they were intended to replace.

The deepest claim in this debate is the one that is hardest to operationalize: that addiction's root conditions — poverty, trauma, social disconnection, housing instability, childhood adversity — are not addressable by any system whose primary tool is supervision. This claim is almost certainly true of the most severe cases and the most entrenched patterns. It is less clearly true of people at earlier stages of a substance use disorder, for whom access to treatment at a moment of crisis — however imperfectly delivered — may redirect a trajectory that would otherwise worsen. The structural critique is strongest as a critique of the system's defaults; it is weakest as a complete alternative, because the community infrastructure it envisions is not yet built in most places, and the people in the system now need something to be true in the meantime.